Eloxx Pharmaceuticals annual free cash flow
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2021
2022
Eloxx Pharmaceuticals Free Cash Flow (FCF) History (ELOX)
Eloxx Pharmaceuticals reported −$31.9M in free cash flow for fiscal 2022, an increase of $3.2M from the previous fiscal year.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2022 | 2022-12-31 | −$31.9M | $3.2M | — | — |
| 2021 | 2021-12-31 | −$35.1M | — | — | — |
| 2019 | 2019-12-31 | −$39.4M | −$7.8M | — | — |
| 2018 | 2018-12-31 | −$31.6M | −$15.4M | — | — |
| 2017 · Dec 31 | 2017-12-31 | −$16.2M | −$7.3M | — | — |
| 2017 · Jun 30 | 2017-06-30 | −$1.9M | $1.7M | — | — |
| 2016 · Dec 31 | 2016-12-31 | −$8.9M | −$3.1M | — | — |
| 2016 · Jun 30 | 2016-06-30 | −$3.7M | $3.8M | — | — |
| 2015 · Dec 31 | 2015-12-31 | −$5.7M | — | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$7.5M | −$2.6M | — | — |
| 2014 | 2014-06-30 | −$4.9M | −$967,420 | — | −2673.19% |
| 2013 | 2013-06-30 | −$3.9M | $486,603 | — | −49928.47% |
| 2012 | 2012-06-30 | −$4.4M | $1.0M | — | −2195.25% |
| 2011 | 2011-06-30 | −$5.4M | −$649,223 | — | — |
| 2010 | 2010-06-30 | −$4.7M | — | — | −3388.75% |
Eloxx Pharmaceuticals quarterly free cash flow
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | −$3.5M | $3.5M | — | — |
| Q2 2023 | 2023-06-30 | −$2.1M | $7.7M | — | — |
| Q1 2023 | 2023-03-31 | −$6.8M | $2.7M | — | — |
| Q4 2022 | 2022-12-31 | −$5.7M | — | — | — |
| Q3 2022 | 2022-09-30 | −$7.0M | — | — | — |
| Q2 2022 | 2022-06-30 | −$9.8M | — | — | — |
| Q1 2022 | 2022-03-31 | −$9.5M | — | — | — |
| Q4 2019 | 2019-12-31 | −$9.3M | −$95,000 | — | — |
| Q3 2019 | 2019-09-30 | −$11.3M | −$3.2M | — | — |
| Q2 2019 | 2019-06-30 | −$9.6M | −$1.1M | — | — |
| Q1 2019 | 2019-03-31 | −$9.2M | −$3.5M | — | — |
| Q4 2018 | 2018-12-31 | −$9.2M | −$15.4M | — | — |
| Q3 2018 | 2018-09-30 | −$8.1M | −$7.5M | — | — |
| Q2 2018 | 2018-06-30 | −$8.6M | −$5.4M | — | — |
| Q1 2018 · Mar 31 | 2018-03-31 | −$5.8M | −$2.9M | — | — |
| Q4 2017 | 2017-12-31 | $6.2M | — | — | — |
| Q1 2018 · Sep 30 | 2017-09-30 | −$634,324 | — | — | — |
| Q4 2017 · Jun 30 | 2017-06-30 | −$3.2M | −$2.5M | — | — |
| Q1 2017 · Mar 31 | 2017-03-31 | −$2.8M | −$2.0M | — | — |
| Q4 2016 | 2016-06-30 | −$714,786 | $1.7M | — | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$840,979 | $616,751 | — | — |
| Q4 2015 | 2015-12-31 | −$988,296 | $581,529 | — | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$1.1M | $881,570 | — | — |
| Q4 2015 | 2015-06-30 | −$2.4M | −$1.2M | — | — |
| Q3 2015 | 2015-03-31 | −$1.5M | $99,739 | — | — |
| Q2 2015 | 2014-12-31 | −$1.6M | −$147,886 | — | — |
| Q1 2015 | 2014-09-30 | −$2.0M | −$1.3M | — | — |
| Q4 2014 | 2014-06-30 | −$1.2M | −$275,126 | — | — |
| Q3 2014 | 2014-03-31 | −$1.6M | $196,960 | — | — |
| Q2 2014 | 2013-12-31 | −$1.4M | −$856,524 | — | — |
| Q1 2014 | 2013-09-30 | −$670,465 | −$32,730 | — | — |
| Q4 2013 | 2013-06-30 | −$946,328 | $385,282 | — | — |
| Q3 2013 | 2013-03-31 | −$1.8M | −$774,407 | — | — |
| Q2 2013 | 2012-12-31 | −$565,415 | $741,322 | — | — |
| Q1 2013 | 2012-09-30 | −$637,735 | $581,342 | — | — |
| Q4 2012 | 2012-06-30 | −$1.3M | −$308,064 | — | — |
| Q3 2012 | 2012-03-31 | −$980,022 | $310,080 | — | — |
| Q2 2012 | 2011-12-31 | −$1.3M | $165,438 | — | −653.37% |
| Q1 2012 | 2011-09-30 | −$1.2M | $388,568 | — | — |
| Q4 2011 | 2011-06-30 | −$1.0M | — | — | — |
| Q3 2011 | 2011-03-31 | −$1.3M | — | — | — |
| Q2 2011 | 2010-12-31 | −$1.5M | — | — | — |
| Q1 2011 | 2010-09-30 | −$1.6M | — | — | — |
Eloxx Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$16.2M to −$31.9M, a net decrease of $15.7M. Eloxx Pharmaceuticals's latest reported quarter, Q3 2023, generated −$3.5M in free cash flow, an increase of $3.5M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
